BRPI1007313A2 - derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. - Google Patents

derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.

Info

Publication number
BRPI1007313A2
BRPI1007313A2 BRPI1007313A BRPI1007313A BRPI1007313A2 BR PI1007313 A2 BRPI1007313 A2 BR PI1007313A2 BR PI1007313 A BRPI1007313 A BR PI1007313A BR PI1007313 A BRPI1007313 A BR PI1007313A BR PI1007313 A2 BRPI1007313 A2 BR PI1007313A2
Authority
BR
Brazil
Prior art keywords
fgf21 derivatives
albumin ligand
albumin
ligand
fgf21
Prior art date
Application number
BRPI1007313A
Other languages
English (en)
Inventor
Birgit Wieczorek
Birgitte Andersen
Henning Thøgersen
Helle WÖLDIKE
Jishu Wang
Kilian Waldemar Conde Frieboes
Kristian Sass Bak-Jensen
Patrick William Garibay
Peter Kresten Nielsen
Rita Slaaby
Tina Møller Tagmose
Xujia Zhang
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of BRPI1007313A2 publication Critical patent/BRPI1007313A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
BRPI1007313A 2009-01-23 2010-01-22 derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso. BRPI1007313A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP09151227 2009-01-23
EP09152144 2009-02-05
EP09164904 2009-07-08
PCT/EP2010/050720 WO2010084169A2 (en) 2009-01-23 2010-01-22 Fgf21 derivatives with albumin binder a-b-c-d-e- and their use

Publications (1)

Publication Number Publication Date
BRPI1007313A2 true BRPI1007313A2 (pt) 2016-02-10

Family

ID=42356264

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1007313A BRPI1007313A2 (pt) 2009-01-23 2010-01-22 derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.

Country Status (14)

Country Link
US (1) US9480753B2 (pt)
EP (1) EP2389190B1 (pt)
JP (1) JP5599822B2 (pt)
KR (1) KR20110117666A (pt)
CN (1) CN102361647B (pt)
AU (1) AU2010207721B2 (pt)
BR (1) BRPI1007313A2 (pt)
CA (1) CA2748593A1 (pt)
ES (1) ES2692495T3 (pt)
IL (1) IL213848A (pt)
MX (1) MX2011007544A (pt)
RU (1) RU2525393C2 (pt)
TW (1) TWI494127B (pt)
WO (1) WO2010084169A2 (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
PL2068909T3 (pl) 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
US9120871B2 (en) 2009-01-23 2015-09-01 Novo Nordisk A/S Process for preparing FGF21 with low degree of O-glycosylation
ES2692495T3 (es) 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
EP2526117B1 (en) 2010-01-22 2015-05-06 Novo Nordisk A/S Process for preparing fgf-21 with low degree of o-glycosylation
US20110236582A1 (en) * 2010-03-29 2011-09-29 Scheuing David R Polyelectrolyte Complexes
CA2796459C (en) 2010-04-16 2016-05-24 Salk Institute For Biological Studies Methods for treating metabolic disorders using fgf-1
CN103124562A (zh) * 2010-06-08 2013-05-29 诺沃—诺迪斯克有限公司 Fgf21的类似物和衍生物
JP2013533227A (ja) * 2010-06-08 2013-08-22 ノヴォ ノルディスク アー／エス Ｆｇｆ２１類似体および誘導体
CN103415300B (zh) * 2010-07-20 2018-02-23 诺沃—诺迪斯克有限公司 N‑末端修饰的fgf21化合物
CN102465129B (zh) * 2010-08-16 2016-05-25 重庆富进生物医药有限公司 人成纤维细胞生长因子21原核细胞中可溶性表达及制备
US9023791B2 (en) * 2010-11-19 2015-05-05 Novartis Ag Fibroblast growth factor 21 mutations
UY34347A (es) 2011-09-26 2013-04-30 Novartis Ag Proteínas de función dual para tratar trastornos metabólicos
LT2814844T (lt) 2012-02-15 2017-10-25 Novo Nordisk A/S Antikūnai, kurie jungiasi ir blokuoja ekspresuotą ant mieloidinių ląstelių inicijuojantį receptorių 1 (trem-1)
LT2814842T (lt) 2012-02-15 2018-11-12 Novo Nordisk A/S Antikūnai, kurie suriša peptidoglikaną atpažįstantį baltymą 1
US9550830B2 (en) 2012-02-15 2017-01-24 Novo Nordisk A/S Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (TREM-1)
US9475856B2 (en) 2012-03-02 2016-10-25 New York University Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders
US9464126B2 (en) 2012-06-07 2016-10-11 New York University Chimeric fibroblast growth factor 21 proteins and methods of use
US9657075B2 (en) 2012-06-07 2017-05-23 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US9474785B2 (en) 2012-06-07 2016-10-25 New York University Chimeric fibroblast growth factor 19 proteins and methods of use
TWI513705B (zh) 2012-06-11 2015-12-21 Lilly Co Eli 纖維母細胞生長因子２１蛋白質
KR20150006059A (ko) 2012-06-11 2015-01-15 일라이 릴리 앤드 캄파니 섬유모세포 성장 인자 21 변이체
WO2014130659A1 (en) 2013-02-22 2014-08-28 New York University Chimeric fibroblast growth factor 23 proteins and methods of use
US20160235810A1 (en) 2013-10-18 2016-08-18 Novartis Ag Methods of treating diabetes and related disorders
CA2928135A1 (en) 2013-10-21 2015-04-30 Salk Institute For Biological Studies Mutated fibroblast growth factor (fgf) 1 and methods of use
WO2015138278A1 (en) 2014-03-11 2015-09-17 Novartis Ag Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling
CN106536559B (zh) 2014-07-17 2021-04-27 诺和诺德股份有限公司 定点诱变trem-1抗体以降低黏度
CN107108710B (zh) 2014-10-24 2022-02-15 百时美施贵宝公司 修饰的fgf-21多肽及其用途
HUE044783T2 (hu) 2014-12-23 2019-11-28 Novo Nordisk As FGF21 származékok és alkalmazásaik
KR102670157B1 (ko) * 2015-10-28 2024-05-29 주식회사유한양행 이중 작용 단백질 및 이를 포함하는 약학적 조성물
AU2016344134A1 (en) 2015-10-30 2018-05-31 Salk Institute For Biological Studies Treatment of steroid-induced hyperglycemia with fibroblast growth factor (FGF) 1 analogs
KR20170080526A (ko) * 2015-12-31 2017-07-10 한미약품 주식회사 Fgf21 아날로그, fgf21 결합체, 및 이의 용도
WO2017180988A2 (en) * 2016-04-15 2017-10-19 Indiana University Research And Technology Corporation Fgf21 c-terminal peptide optimization
MA45113A (fr) 2016-05-24 2019-04-10 Novo Nordisk As Composés mic-1 et leur utilisation
US11123438B2 (en) 2016-08-19 2021-09-21 Ampsource Biopharma Shanghai Inc. Linker peptide for constructing fusion protein
CN107759694B (zh) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 双特异性抗体及其制备方法与用途
CN106279437B (zh) 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 高糖基化人凝血因子viii融合蛋白及其制备方法与用途
AU2018256256B2 (en) 2017-04-21 2023-02-23 Yuhan Corporation Method for producing dual function proteins and its derivatives
TWI710377B (zh) * 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
IL275499B2 (en) 2017-12-22 2024-03-01 Novartis Ag Methods of treating metabolic disorders with fgf21 variants
TWI790370B (zh) 2018-04-02 2023-01-21 美商必治妥美雅史谷比公司 抗trem-1抗體及其用途
US12226451B2 (en) 2018-07-03 2025-02-18 Bristol-Myers Squibb Company FGF-21 formulations
US11542309B2 (en) 2019-07-31 2023-01-03 Salk Institute For Biological Studies Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose
CN115322794B (zh) * 2020-01-11 2025-09-19 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物
US11981718B2 (en) 2020-05-27 2024-05-14 Ampsource Biopharma Shanghai Inc. Dual-function protein for lipid and blood glucose regulation
CA3224743A1 (en) 2021-07-14 2023-01-19 Beijing Ql Biopharmaceutical Co., Ltd. Fusion polypeptides for metabolic disorders
CN113980147B (zh) * 2021-11-26 2023-07-28 中国药科大学 一种聚多肽与fgf21融合蛋白突变体及其应用
EP4700044A1 (en) * 2023-03-31 2026-02-25 Shanghai Duomirui Biotechnology., Ltd. Protein analogue and use thereof
CN120157578B (zh) * 2025-03-17 2025-11-18 质肽药业(泰州)有限公司 一种十八烷二酸单叔丁酯的制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
IL128332A0 (en) 1996-08-30 2000-01-31 Novo Nordisk As GLP-1 derivatives
WO2001032678A1 (en) 1999-11-05 2001-05-10 Smithkline Beecham Corporation sbgFGF-19a
US20040259780A1 (en) 2001-07-30 2004-12-23 Glasebrook Andrew Lawrence Method for treating diabetes and obesity
EP1329227A1 (en) 2002-01-22 2003-07-23 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Diagnostic conjugate useful for intercellular imaging and for differentiating between tumor- and non-tumor cells
KR101159559B1 (ko) 2003-08-05 2012-06-26 노보 노르디스크 에이/에스 신규의 인슐린 유도체
CN101380476A (zh) * 2003-09-19 2009-03-11 诺沃挪第克公司 治疗肽的清蛋白结合型衍生物
JP2007537981A (ja) * 2003-09-19 2007-12-27 ノボ　ノルディスク　アクティーゼルスカブ 新規の血漿タンパク質親和性タグ
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
RU2401276C2 (ru) * 2003-09-19 2010-10-10 Ново Нордиск А/С Производные глюкагон-подобного пептида-1 (glp-1)
AU2004303783A1 (en) 2003-12-10 2005-07-07 Eli Lilly And Company Muteins of fibroblast growth factor 21
BRPI0417684A (pt) * 2003-12-18 2007-03-20 Novo Nordisk As composto, composição farmacêutica, e, uso de um composto
JP2007531715A (ja) 2004-03-17 2007-11-08 イーライ リリー アンド カンパニー グリコール結合ｆｇｆ−２１化合物
DK1751184T3 (da) * 2004-05-13 2009-11-23 Lilly Co Eli FGF-21 fusionsproteiner
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
ES2542228T3 (es) * 2004-07-08 2015-08-03 Novo Nordisk A/S Marcas de prolongación polipeptídica que comprenden un resto de tetrazol
MX2007002616A (es) 2004-09-02 2007-05-16 Lilly Co Eli Muteinas de factor de crecimiento de fibroblasto 21.
WO2006028714A1 (en) 2004-09-02 2006-03-16 Eli Lilly And Company Muteins of fibroblast growth factor 21
EP1814573B1 (en) * 2004-10-29 2016-03-09 ratiopharm GmbH Remodeling and glycopegylation of fibroblast growth factor (fgf)
US7655627B2 (en) 2004-12-14 2010-02-02 Eli Lilly And Company Muteins of fibroblast growth factor 21
US20080261875A1 (en) 2005-01-21 2008-10-23 Eli Lilly And Company Method For Treating Cardiovascular Disease
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
US20100022446A1 (en) * 2007-01-18 2010-01-28 Novo Nordisk A/S Use of Peptides in Combination with Surgical Intervention for the Treatment of Obesity
PL2068909T3 (pl) * 2007-03-30 2012-09-28 Ambrx Inc Modyfikowane polipeptydy fgf-21 i ich zastosowanie
JP2010535781A (ja) 2007-08-03 2010-11-25 イーライ リリー アンド カンパニー 肥満に対する処置
US20100261637A1 (en) 2007-09-05 2010-10-14 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN100587073C (zh) * 2008-03-24 2010-02-03 吉林农大生物反应器工程有限公司 人成纤维细胞生长因子-21的重组表达
EP2358749B1 (en) 2008-10-10 2018-07-18 Amgen, Inc Fgf21 mutants and uses thereof
WO2010065439A1 (en) 2008-12-05 2010-06-10 Eli Lilly And Company Variants of fibroblast growth factor 21
ES2692495T3 (es) 2009-01-23 2018-12-03 Novo Nordisk A/S Derivados del FGF21 con aglutinante de albúmina A-B-C-D-E- y sus usos
US20120172298A1 (en) 2009-06-11 2012-07-05 Novo Nordisk A/S Glp-1 and fgf21 combinations for treatment of diabetes type 2
US20120035099A1 (en) * 2009-06-11 2012-02-09 Novo Nordisk A/S Fgf21 analogues and derivatives

Also Published As

Publication number Publication date
AU2010207721A1 (en) 2011-07-28
CN102361647B (zh) 2018-02-16
EP2389190B1 (en) 2018-09-19
JP5599822B2 (ja) 2014-10-01
US20100216715A1 (en) 2010-08-26
IL213848A0 (en) 2011-07-31
RU2011134454A (ru) 2013-02-27
RU2525393C2 (ru) 2014-08-10
WO2010084169A3 (en) 2011-02-17
EP2389190A2 (en) 2011-11-30
US9480753B2 (en) 2016-11-01
CA2748593A1 (en) 2010-07-29
KR20110117666A (ko) 2011-10-27
AU2010207721B2 (en) 2015-03-26
MX2011007544A (es) 2011-08-12
TWI494127B (zh) 2015-08-01
TW201032827A (en) 2010-09-16
WO2010084169A2 (en) 2010-07-29
CN102361647A (zh) 2012-02-22
ES2692495T3 (es) 2018-12-03
JP2012515747A (ja) 2012-07-12
IL213848A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
BRPI1007313A2 (pt) derivados de fgf21 com ligante de albumina a-b-c-d-e e seu uso.
CY2023012I1 (el) Παραγωγα κινολιν-8-σουλφοναμιδιου εχοντα αντικαρκινικη δραση
BRPI0808098A2 (pt) 4-aril-1,4-di-hidro-1,6-naftiridinamidas substituídas e seu uso
BRPI1016117A8 (pt) derivados de isoxazol-isoxazol e isoxazol-isotiazol.
BRPI1010881A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI1010882A2 (pt) derivados de triazina e suas aplicações terapêuticas.
BRPI0814267A2 (pt) Agentes citotóxicos compreendendo novos derivados de tomaicmicina e o seu uso terapêutico.
BRPI1012598A2 (pt) Prendedor cego com característica de anti- rotação integrada, sistemas e métodos
BRPI1008740A2 (pt) Proteínas pesticidas e métodos para seu uso.
BRPI0813909A2 (pt) Seringa com mecanismo de inutilização
BRPI1010621A2 (pt) derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI1010533A2 (pt) tetrahidroazolopirazinas sulfoniladas e seu uso como medicamentos
BRPI1011527A2 (pt) derivados de triazina substituídos com ureidofenil e suas aplicações terapêuticas.
BRPI1009221A2 (pt) proteínas de fusão transcriptase reversa estabilizadas.
HRP20161562T1 (hr) Derivati benzimidazola
BRPI1010024A2 (pt) derivados de aminopirrolidinona e uso dos mesmos
BRPI0816372A2 (pt) Ácidos 6-fenilnicotínicos substituídos e seu uso
BRPI0913885A8 (pt) tiadiazoliloxifenilamidinas e seu uso como fungicidas
BRPI0819258A2 (pt) alguns derivados de 2-pirazinona e seu uso como inibidores da elastase neutrófila
BRPI0810654A2 (pt) Tiadiazoliloxifenilamidinas e o seu uso como fungicidas.
NL2003100A1 (nl) Track system with adjustable width.
BRPI0808846A2 (pt) fenoxifenilamidinas 3-substituídas e seu uso como fungicidas
BRPI1011960A2 (pt) combinações herbicidas compreendendo tefuriltriona para uso em culturas de arroz.
BRPI1015365A2 (pt) colher dosadora com grampo.
BRPI0814231A2 (pt) Derivados de pleuromutilina e seu uso como antimicrobianos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 47/54 (2017.01), A61K 47/60 (2017.01), A61K 4

B350 Update of information on the portal [chapter 15.35 patent gazette]